Status:
COMPLETED
The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
Lead Sponsor:
Virginia Center for Reproductive Medicine
Conditions:
Ovarian Hyperstimulation Syndrome
Eligibility:
FEMALE
19-32 years
Phase:
NA
Brief Summary
This pilot study aims to address whether the prophylactic use of Cetrorelix Acetate after a long gonadotropin-releasing hormone (GnRH) agonist protocol post-hCG (human chorionic gonadotropin) administ...
Detailed Description
With varying complications, OHSS is an iatrogenic condition cause by ovarian stimulation. Classified as mild, moderate, or severe, mild OHSS is relatively common as it occurs in up to 1/3 of women und...
Eligibility Criteria
Inclusion
- Prospective donors with BMIs between 19 and 28,
- Those with normal FSH levels and good antral follicle counts between 19-28 years of age, AND
- Donors would have passed all the required testing as mandated by VCRM and the FDA.
Exclusion
- Oocyte donors exceeding a BMI of \> 28,
- Those with any communicable diseases,
- Those with low antral follicle counts and small ovarian volumes,
- Those with elevated FSH levels,
- Those with positive sickle cell screen or cystic fibrosis screening,
- Smokers, OR
- Donors who are unable or unwilling to follow the research protocols.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00867659
Start Date
March 1 2009
End Date
October 1 2011
Last Update
March 27 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Center for Reproductive Medicine
Reston, Virginia, United States, 20190